Literature DB >> 18765846

Feedlot health and performance effects associated with the timing of respiratory disease treatment.

A H Babcock1, B J White, S S Dritz, D U Thomson, D G Renter.   

Abstract

Generalized linear mixed models were developed using retrospective feedlot data collected on individually treated cattle (n = 31,131) to determine whether cattle performance and health outcomes in feedlot cattle were associated with timing of treatment for bovine respiratory disease (BRD) during the feeding phase. Cattle that died at any point during the feeding phase were removed from the analysis. Information on individual animal performance (ADG, HCW, quality grade, yield grade) and health outcomes (treatments) were incorporated into an economic model that generated a standardized net return estimate for each animal. Prices were standardized to minimize variation between economic outcomes due to market conditions allowing direct comparisons of health and performance effects between animals. While controlling for sex, risk code, and arrival BW class, potential associations between net returns and the timing of BRD identification were investigated using 2 categorical variables created to measure time: 1) weeks on feed at initial BRD treatment, and 2) weeks from BRD treatment to slaughter. The first model using net return as the outcome identified an interaction between weeks on feed at initial BRD treatment and animal arrival BW. Cattle with arrival BW between 227 and 272 kg (5WT) and 273 and 318 kg (6WT) displayed decreased net returns (P < 0.05) if treated during wk 1 as compared with subsequent weeks in the first month of the feeding phase. The cattle with BW between 319 and 363 kg (7WT) and 364 and 408 kg (8WT) exhibited decreased net returns (P < 0.05) if treated during the later weeks of the feeding phase compared with earlier in the feeding phase. The number of times cattle were treated contributed to variation in net returns for the 5WT and 6WT cattle. For the 7WT and 8WT cattle, HCW was the main factor contributing to decreased net returns when cattle were treated late in the feeding phase. The second model identified an interaction between weeks from BRD treatment to slaughter and arrival BW. The 181 to 226 kg of BW, 5WT, 6WT, 7WT, and 8WT cattle all exhibited decreased net returns (P < 0.05) when cattle were on feed fewer weeks from BRD treatment to slaughter. Cattle with more weeks on feed between BRD treatment and slaughter had greater HCW, decreased ADG, and more total treatments compared with cattle treated closer to slaughter. This research indicates that timing of initial BRD treatment is associated with performance and health outcomes.

Entities:  

Mesh:

Year:  2008        PMID: 18765846     DOI: 10.2527/jas.2008-1201

Source DB:  PubMed          Journal:  J Anim Sci        ISSN: 0021-8812            Impact factor:   3.159


  13 in total

1.  Limited efficacy of Fever Tag(®) temperature sensing ear tags in calves with naturally occurring bovine respiratory disease or induced bovine viral diarrhea virus infection.

Authors:  Robert McCorkell; Katherine Wynne-Edwards; Claire Windeyer; Al Schaefer
Journal:  Can Vet J       Date:  2014-07       Impact factor: 1.008

2.  Association between antimicrobial drug class selection for treatment and retreatment of bovine respiratory disease and health, performance, and carcass quality outcomes in feedlot cattle.

Authors:  Johann F Coetzee; Natalia Cernicchiaro; Pritam K Sidhu; Michael D Kleinhenz
Journal:  J Anim Sci       Date:  2020-04-01       Impact factor: 3.159

3.  Comparison of enrofloxacin and ceftiofur sodium for the treatment of relapse of undifferentiated fever/bovine respiratory disease in feedlot cattle.

Authors:  Sameeh M Abutarbush; Oliver C Schunicht; Brian K Wildman; Sherry J Hannon; G Kee Jim; Tracy I Ward; Calvin W Booker
Journal:  Can Vet J       Date:  2012-01       Impact factor: 1.008

4.  Predicting cumulative risk of bovine respiratory disease complex (BRDC) using feedlot arrival data and daily morbidity and mortality counts.

Authors:  Abram H Babcock; Brad J White; David G Renter; Suzanne R Dubnicka; H Morgan Scott
Journal:  Can J Vet Res       Date:  2013-01       Impact factor: 1.310

5.  Linking disease epidemiology and livestock productivity: The case of bovine respiratory disease in France.

Authors:  Alexis Delabouglise; Andrew James; Jean-François Valarcher; Sara Hagglünd; Didier Raboisson; Jonathan Rushton
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

6.  Whole blood transcriptomic analysis of beef cattle at arrival identifies potential predictive molecules and mechanisms that indicate animals that naturally resist bovine respiratory disease.

Authors:  Matthew A Scott; Amelia R Woolums; Cyprianna E Swiderski; Andy D Perkins; Bindu Nanduri; David R Smith; Brandi B Karisch; William B Epperson; John R Blanton
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

7.  Selecting sorting centres to avoid long distance transport of weaned beef calves.

Authors:  T Morel-Journel; E Vergu; J-B Mercier; N Bareille; P Ezanno
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

8.  Impact of respiratory disease, diarrhea, otitis and arthritis on mortality and carcass traits in white veal calves.

Authors:  Bart Pardon; Miel Hostens; Luc Duchateau; Jeroen Dewulf; Koen De Bleecker; Piet Deprez
Journal:  BMC Vet Res       Date:  2013-04-15       Impact factor: 2.741

9.  Effect of bovine respiratory disease during the receiving period on steer finishing performance, efficiency, carcass characteristics, and lung scores.

Authors:  B K Wilson; D L Step; C L Maxwell; C A Gifford; C J Richards; C R Krehbiel
Journal:  Prof Anim Sci       Date:  2017-01-23

10.  Economic effects of policy options restricting antimicrobial use for high risk cattle placed in U.S. feedlots.

Authors:  Guillaume Lhermie; Pierre Sauvage; Loren William Tauer; Leslie Verteramo Chiu; Karun Kanyiamattam; Ahmed Ferchiou; Didier Raboisson; Harvey Morgan Scott; David R Smith; Yrjo Tapio Grohn
Journal:  PLoS One       Date:  2020-09-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.